Skip to main content

Turkey begins vaccine trials with foreign drugmakers

Turkey's health minister has announced the start of human trials in Turkey with Chinese, US and Russian vaccines and says the end of the crisis is in sight.

A nurse prepares a shot of the A(H1N1) vaccine (Pandemrix from Glaxo Smith Kline -GSK- laboratory) to a hospital staff member in Istanbul, on November 2, 2009. Turkey began vaccinating medical workers Monday as the death toll from the A(H1N1) virus in the country reached six, the health ministry said.   The latest victims of the disease were a 22-month-old baby and a 14-year-old boy who died overnight in the central city of Konya, a ministry statement said. Nine other people infected with swine flu were in
A nurse prepares a shot of the A(H1N1) vaccine (Pandemrix from Glaxo Smith Kline -GSK- laboratory) to a hospital staff member in Istanbul, on Nov. 2, 2009. — BULENT KILIC/AFP via Getty Images

ISTANBUL — Turkey is starting clinical trials of potential vaccines for the novel coronavirus, working with drugmakers in China, the United States and other countries.

On Wednesday, three Turkish health workers at an Ankara research hospital began Phase III trials of Chinese manufacturer Sinovac Biotech’s vaccine, Health Minister Fahrettin Koca said at a news conference after a meeting with the government’s coronavirus task force. The trial will eventually be expanded to 10,000 volunteers and the vaccine’s effectiveness in creating antibodies will become clear within a month.

Turkey will also participate in US drugmaker Pfizer’s clinical trials of a coronavirus vaccine that will soon begin in Istanbul, he said late on Wednesday. It may approve Phase III trials of a Russian treatment as early as next week once it determines that problems with the drug have been resolved, he said. He did not specify the problems. 

“Our citizens may have genetic or regional differences. To see if this has an impact, we believe it is important to take different actions. So we are not working with just these three vaccines but are closely cooperating on other vaccines,” Koca said. “We are engaged in efforts to obtain at an early stage the vaccine that gives us confidence and results.”

SUBSCRIBER EXCLUSIVE

Continue reading this exclusive analysis

Original reporting and analysis unavailable elsewhere. Subscribe to AL-MONITOR to read this story and access everything we publish